Nanomedicine: Nanotechnology, Biology and Medicine
Original ArticleFenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice
Graphical Abstract
Mice were fed with an MCD diet seven days ahead to develop NAFLD, and were then treated with saline, FNB crude drug or FNB-Nanolipo by gavage and meanwhile continuously fed with the MCD diet for another seven days. Compared to the FNB crude drug, the FNB-Nanolipo significantly enhanced oral absorption of FNB and therefore, significantly cured NAFLD induced by the MCD diet.
Section snippets
Materials and animals
FNB was purchased from Kaifeng Pharmaceutical Co. Ltd. (Henan, China). Soybean lecithin was purchased from Tywei Pharmaceutical Co. Ltd. (Shanghai, China). Cholesterol was purchased from Damao Chemical Reagent Factory (Tianjin, China). Fenofibrate acid was purchased from J&K Scientific Ltd. (Beijing, China). HPLC-grade acetonitrile was purchased from Sigma-Aldrich (MO, USA). High-fat MCD diet was purchased from Trophic Animal Feed High-tech Co., Ltd. (Jiangsu, China).
Male C57BL/6 wild type mice
Characterizations of the FNB-Nanolipo
Data in Table 1 show that particle size of the FNB-Nanolipo determined by dynamic light scattering was 122.1 ± 1.40 nm, and polydispersity index (PDI) was 0.293, showing a uniform size distribution. Zeta potential was slightly electronegative (−2.92 mV).
Encapsulation efficacy and drug loading percentage of the FNB-Nanolipo were 96.6 ± 1.60% and 7.44 ± 4.39%, respectively.
Morphology and in vitro release of the FNB-Nanolipo
The TEM photo (Figure 1, A) shows that the FNB-Nanolipo had a spherical shape, and the particle size was between 100 and 140 nm,
Discussion
Encapsulation efficacy and drug loading percentage are important characterization parameters used to measure the ability of nanoliposomes to encapsulate drug molecules. The high encapsulation efficacy (96.6 ± 1.60%) and drug loading percentage (7.44 ± 4.39%) indicate that most of the FNB in the formulation was incorporated into the nanoliposome vesicles. The drug loading capacity was higher than some other formulations of FNB reported in the literature, including self-microemulsifying drug delivery
References (43)
- et al.
Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes
Clin Gastroenterol Hepatol
(2015) - et al.
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Gastroenterology
(2012) - et al.
The utility of radiological imaging in nonalcoholic fatty liver disease
Gastroenterology
(2002) - et al.
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
Gastroenterology
(2005) - et al.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Lancet
(2009) - et al.
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
J Biol Chem
(1999) - et al.
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
Eur J Pharmacol
(2013) - et al.
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Dig Liver Dis
(2008) - et al.
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
J Hepatol
(2006) - et al.
Drug delivery vehicles on a nano-engineering perspective
Mater Sci Eng C Mater Biol Appl
(2014)
Preparation and characterization of liposomes as therapeutic delivery systems: a review
Pharm Acta Helv
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
J Lipid Res
The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes
J Biol Chem
A novel approach for the development and optimization of self emulsifying drug delivery system using HLB and response surface methodology: application to fenofibrate encapsulation
Int J Pharm
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug
Adv Drug Deliv Rev
Drug entrapment in liposomes
FEBS Lett
Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms
J Pharm Sci
Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium
Eur J Pharm Sci
Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability
Colloids Surf B Biointerfaces
A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate
Eur J Pharm Biopharm
G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin
Nanomedicine
Cited by (0)
Conflict of interest: We have no conflict of interest to declare.
- 1
These two authors contribute equally to this paper.